3,266 Eli Lilly and Company $LLY Shares Acquired by Moors & Cabot Inc.

Moors & Cabot Inc. lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 14.3% during the third quarter, Holdings Channel.com reports. The fund owned 26,106 shares of the company’s stock after acquiring an additional 3,266 shares during the period. Eli Lilly and Company accounts for approximately 1.1% of Moors & Cabot Inc.’s holdings, making the stock its 12th biggest holding. Moors & Cabot Inc.’s holdings in Eli Lilly and Company were worth $30,206,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of LLY. Torren Management LLC boosted its stake in Eli Lilly and Company by 357.1% in the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after purchasing an additional 25 shares in the last quarter. Marshall & Sterling Wealth Advisors Inc. grew its position in Eli Lilly and Company by 60.0% during the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after purchasing an additional 15 shares during the last quarter. Foresight Capital Management Advisors Inc. purchased a new stake in Eli Lilly and Company during the 3rd quarter worth approximately $49,000. AlphaCentric Advisors LLC purchased a new stake in Eli Lilly and Company during the 1st quarter worth approximately $42,000. Finally, Caitlin John LLC purchased a new stake in Eli Lilly and Company during the 2nd quarter worth approximately $64,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,444.05 on Monday. Eli Lilly and Company has a twelve month low of $850.51 and a twelve month high of $1,460.00. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The company has a market cap of $1.36 trillion, a PE ratio of 46.87, a price-to-earnings-growth ratio of 1.73 and a beta of 0.40. The company’s 50 day moving average is $1,242.25 and its 200 day moving average is $1,110.30.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business had revenue of $24.40 billion during the quarter, compared to analysts’ expectations of $22.58 billion. During the same period in the previous year, the business posted $7.02 EPS. The business’s quarterly revenue was up 38.6% compared to the same quarter last year. On average, sell-side analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Friday, November 13th will be paid a $1.73 dividend. The ex-dividend date is Friday, November 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.5%. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on LLY. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a research note on Monday, November 9th. UBS Group lifted their price objective on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Leerink Partners boosted their price objective on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a report on Wednesday, October 21st. Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price on the stock in a research report on Tuesday, September 15th. Finally, Truist Financial reissued a “buy” rating and issued a $1,612.00 target price (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,416.64.

Check Out Our Latest Research Report on Eli Lilly and Company

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.